{"disease":{"id":"systemic-lupus-erythematosus","name":"Systemic Lupus Erythematosus (SLE)","therapeutic_area":"Immunology & Inflammation","data":{"aiSummary":"The treatment landscape for SLE involves a combination of symptomatic management and disease-modifying therapies. Current standard of care includes corticosteroids, antimalarials, and immunosuppressants. Belimumab is a targeted biologic approved for SLE. Recent advances include the development of new targeted therapies, such as medi-546, which are in clinical trials. The pipeline outlook includes further development of novel biologics and small molecules aimed at improving outcomes and reducing the need for corticosteroids.","drug_count":7,"description":"Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by the immune system attacking its own tissues, leading to widespread inflammation and tissue damage. The pathophysiology involves the production of autoantibodies, immune complex deposition, and complement activation, resulting in diverse clinical manifestations. Current treatment focuses on managing symptoms, preventing flares, and minimizing organ damage.","subtype_count":16},"enrichment_level":2,"last_enriched_at":null,"visit_count":0,"created_at":"2026-03-25T12:16:34.967Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":26,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"benlysta","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Benlysta","company_name":"GlaxoSmithKline","drug_phase":"marketed","molecular_target":"Tumor necrosis factor ligand superfamily member 13B","drug_class":"","quality_score":24,"revenue":"1200","mechanism":null},{"drug_id":"belimumab","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lymphostat B","generic_name":"BELIMUMAB","company_name":"Human Genome Sciences Inc.","drug_phase":"marketed","molecular_target":"Tumor necrosis factor ligand superfamily member 13B","drug_class":"B Lymphocyte Stimulator-specific Inhibitor [EPC]","quality_score":59,"revenue":"1100","mechanism":"Belimumab works by blocking the B Lymphocyte Stimulator, a protein that can contribute to the autoimmune response in Systemic lupus erythematosus."},{"drug_id":"anifrolumab","indication_name":"Moderate to severe systemic lupus erythematosus (SLE)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Saphnelo","generic_name":"ANIFROLUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor 1","drug_class":"Type I Interferon Receptor Antagonist [EPC]","quality_score":59,"revenue":"700","mechanism":"Saphnelo blocks the action of interferon alpha/beta, a protein that triggers an immune response."},{"drug_id":"hydrocortisone-succinate","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Solu-Cortef","generic_name":"hydrocortisone succinate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"hydroxychloroquine-pill","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hydroxychloroquine Sulfate","generic_name":"hydroxychloroquine-pill","company_name":"Sanofi","drug_phase":"discontinued","molecular_target":"Toll-like receptor 9","drug_class":"Antimalarial","quality_score":null,"revenue":null,"mechanism":"Hydroxychloroquine Sulfate works by interfering with the replication of malaria parasites and modulating the immune system to treat autoimmune diseases."},{"drug_id":"azathioprine","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imuran","generic_name":"AZATHIOPRINE","company_name":"Legacy Pharma","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Purine Antimetabolite [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-acetate","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortifoam","generic_name":"HYDROCORTISONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"prasterone","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Intrarosa","generic_name":"PRASTERONE","company_name":"","drug_phase":"marketed","molecular_target":"Sex hormone-binding globulin","drug_class":"Non-Standardized Food Allergenic Extract [EPC]","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-acetate","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celestone Soluspan","generic_name":"BETAMETHASONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"advanced-therapy-only-without-dietary-intervention","indication_name":"Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Systemic Lupus Erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advanced therapy only without dietary intervention","generic_name":"advanced-therapy-only-without-dietary-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various cell types","drug_class":"advanced therapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednison","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednison","company_name":"Wen Zhang","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"anifrolumab-fnia","indication_name":"Moderate to severe systemic lupus erythematosus (SLE)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SAPHNELO","generic_name":"ANIFROLUMAB-FNIA","company_name":"ASTRAZENECA AB","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor 1","drug_class":"Type I Interferon Receptor Antagonist [EPC]","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"intrarosa","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Intrarosa","company_name":"Center for Vulvovaginal Disorders","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Beta-glucuronidase, Glucose-6-phosphate 1-dehydrogenase","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolone","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"hydrocortisone","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"prednisone","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"oral-14c-pf-06821497","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oral [14C] PF-06821497","generic_name":"oral-14c-pf-06821497","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"chloroquine","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aralen","generic_name":"CHLOROQUINE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"Antimalarial","quality_score":65,"revenue":null,"mechanism":"Aralen works by accumulating in the acidic compartments of the malaria parasite, disrupting its metabolism and ultimately leading to its death."},{"drug_id":"hydroxychloroquine","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hydroxychloroquine Sulfate","generic_name":"HYDROXYCHLOROQUINE","company_name":"Advanz","drug_phase":"marketed","molecular_target":"Toll-like receptor 9","drug_class":"Antimalarial","quality_score":75,"revenue":null,"mechanism":"Hydroxychloroquine Sulfate works by interfering with the replication of malaria parasites and reducing inflammation in the body."},{"drug_id":"betamethasone","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"cortisol","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolon","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxychloroquin","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxychloroquin","company_name":"Children's Hospital of Fudan University","drug_phase":"marketed","molecular_target":"Transmembrane protein 97, Alpha-1D adrenergic receptor, Alpha-2A adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisone","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"dehydroepiandrosterone","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dehydroepiandrosterone","company_name":"National Institute of Dental and Craniofacial Research (NIDCR)","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Beta-glucuronidase, Glucose-6-phosphate 1-dehydrogenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"dexamethasone-phosphate","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydroxychloroquine","indication_name":"Systemic lupus erythematosus treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hydroxychloroquine Sulfate","generic_name":"HYDROXYCHLOROQUINE","company_name":"Advanz","drug_phase":"marketed","molecular_target":"Toll-like receptor 9","drug_class":"Antimalarial","quality_score":75,"revenue":null,"mechanism":"Hydroxychloroquine Sulfate works by interfering with the replication of malaria parasites and reducing inflammation in the body."}],"pipeline":[],"offLabel":[],"totalMarketed":32,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07431775","title":"Saphnelo Use in Females of Child-bearing Potential","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":26000000,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04239521","title":"The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata","phase":"","overall_status":"COMPLETED","enrollment_count":51955,"lead_sponsor_name":"Momentum Data","has_results":false},{"nct_id":"NCT06927219","title":"Research Accelerated by You Lupus Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Lupus Foundation of America","has_results":false},{"nct_id":"NCT04402086","title":"Rheumatology Patient Registry and Biorepository","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Yale University","has_results":false},{"nct_id":"NCT03138941","title":"Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Monash University","has_results":false},{"nct_id":"NCT07077304","title":"EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT01705977","title":"Belimumab Assessment of Safety in SLE","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":4019,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03802188","title":"Hydroxychloroquine in Systemic Lupus Erythematosus","phase":"","overall_status":"UNKNOWN","enrollment_count":3700,"lead_sponsor_name":"McGill University Health Centre/Research Institute of the McGill University Health Centre","has_results":false},{"nct_id":"NCT07000110","title":"Anifrolumab Malignancy and Serious Infections Study","phase":"","overall_status":"RECRUITING","enrollment_count":3195,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT01729455","title":"Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry","phase":"","overall_status":"COMPLETED","enrollment_count":3138,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03142412","title":"Lupus Interval Monitoring to Manage Disease Flare and Enable Treatment Optimization","phase":"","overall_status":"UNKNOWN","enrollment_count":2500,"lead_sponsor_name":"DxTerity Diagnostics","has_results":false},{"nct_id":"NCT05879419","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2005,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":false},{"nct_id":"NCT00001372","title":"Study of Systemic Lupus Erythematosus","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","has_results":false},{"nct_id":"NCT03735238","title":"Implementing the Decision-Aid for Lupus (IDEAL Strategy)","phase":"","overall_status":"COMPLETED","enrollment_count":1895,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":true},{"nct_id":"NCT04747288","title":"Objective Measurement With TCM Pattern for AIDDES","phase":"","overall_status":"UNKNOWN","enrollment_count":1800,"lead_sponsor_name":"Taipei Veterans General Hospital, Taiwan","has_results":false},{"nct_id":"NCT03370263","title":"BENLYSTA® Special Drug Use Investigation","phase":"","overall_status":"COMPLETED","enrollment_count":1514,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT04749875","title":"Study of Leukocyte Populations in Patients With Chronic Inflammatory","phase":"","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03843125","title":"A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1147,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT00055055","title":"Study of Families With Twins or Siblings Discordant for Rheumatic Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":1056,"lead_sponsor_name":"National Institute of Environmental Health Sciences (NIEHS)","has_results":false},{"nct_id":"NCT07000916","title":"Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Université Catholique de Louvain","has_results":false},{"nct_id":"NCT03276923","title":"Maternal Autoimmune Disease Research Alliance (MADRA) Registry","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT07005479","title":"Long-Term Outcomes in SLE at Peking University People's Hospital","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT06804057","title":"CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"CorEvitas","has_results":false},{"nct_id":"NCT06698900","title":"This Project Aims to Understand the Needs of Rheumatologists and Other Specialties in the Care of Patients With SLE","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03348774","title":"Scrutinizing the Heterogeneity of SLE: Defining Phenotypes","phase":"","overall_status":"UNKNOWN","enrollment_count":950,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT07102030","title":"Subgrouping SLE - a New Approach to Understand the Pathogenesis and Improve Treatment","phase":"","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"Region Stockholm","has_results":false},{"nct_id":"NCT02782039","title":"Register of Patients With Anti-Phospholipids Syndrome (APS) and/or Systemic Lupus Erythematosus (SLE)","phase":"","overall_status":"COMPLETED","enrollment_count":868,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05352919","title":"An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":864,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT01484496","title":"A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":839,"lead_sponsor_name":"Human Genome Sciences Inc., a GSK Company","has_results":true},{"nct_id":"NCT01283139","title":"A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":834,"lead_sponsor_name":"MedImmune LLC","has_results":true},{"nct_id":"NCT03616912","title":"A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":830,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT03189875","title":"Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS)","phase":"","overall_status":"COMPLETED","enrollment_count":830,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03616964","title":"A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":778,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT04976322","title":"A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":760,"lead_sponsor_name":"UCB Biopharma SRL","has_results":false},{"nct_id":"NCT00712933","title":"A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":738,"lead_sponsor_name":"Human Genome Sciences Inc., a GSK Company","has_results":true},{"nct_id":"NCT01345253","title":"GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":709,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT07209540","title":"European LUpuS Inception-Cohort Developing initiATivE","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":700,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT03480529","title":"Monitoring the IMmUological TOXicity of Drugs","phase":"","overall_status":"COMPLETED","enrollment_count":662,"lead_sponsor_name":"Groupe Hospitalier Pitie-Salpetriere","has_results":false},{"nct_id":"NCT00342095","title":"Hormonal and Environmental Risk Factors for Developing Systemic Lupus Erythematosus: The Carolina Lupus (CLU) Study","phase":"","overall_status":"COMPLETED","enrollment_count":640,"lead_sponsor_name":"National Institute of Environmental Health Sciences (NIEHS)","has_results":false},{"nct_id":"NCT06056778","title":"The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)","phase":"","overall_status":"COMPLETED","enrollment_count":628,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07049653","title":"Anifrolumab Pregnancy Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":627,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06759519","title":"Clinical and Demographic Features of Patients With Moderate to Severe Active Systemic Lupus Erythematosus in Russia","phase":"","overall_status":"COMPLETED","enrollment_count":621,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05714930","title":"LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus","phase":"NA","overall_status":"RECRUITING","enrollment_count":606,"lead_sponsor_name":"Heinrich-Heine University, Duesseldorf","has_results":false},{"nct_id":"NCT04942314","title":"Practice of Treat-to-target on Pediatric Systemic Lupus Erythematosus: a Two-center Retrospective Study","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Jia Deng","has_results":false},{"nct_id":"NCT04345159","title":"Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease","phase":"","overall_status":"COMPLETED","enrollment_count":572,"lead_sponsor_name":"Fondation Ophtalmologique Adolphe de Rothschild","has_results":false},{"nct_id":"NCT06485674","title":"Long-Term Organ Damage: Anifrolumab Versus Real-World Standard of Care in Adult Patients With Active Systemic Lupus Erythematosus","phase":"","overall_status":"COMPLETED","enrollment_count":561,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02794285","title":"Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":559,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT05637112","title":"A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":551,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06133972","title":"Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":550,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02950714","title":"Dissemination of the Lupus Interactive Navigator","phase":"NA","overall_status":"COMPLETED","enrollment_count":541,"lead_sponsor_name":"CHU de Quebec-Universite Laval","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}